The Filing Desk

NewAmsterdam Pharma vs Scynexis

NewAmsterdam Pharma NAMS · Scynexis SCYX · Pharmaceuticals

NewAmsterdam Pharma reported revenue of $22 million in fiscal 2025, about the same as Scynexis' $21 million in fiscal 2025. NewAmsterdam Pharma's revenue fell 50.6% in its latest year, and Scynexis' grew 449.9%. NewAmsterdam Pharma had an operating margin of -1002.9%, against -78.0% at Scynexis.

Side by side

NewAmsterdam PharmaScynexis
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$22M$21M
Revenue growth−50.6%449.9%
Revenue growth a year, last 5 years——
Gross margin——
Operating margin−1,002.9%−78.0%
Net margin−905.7%−41.8%
Free cash flow−$148M—
Free cash flow margin−657.8%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count25.5%2.9%
Last close$19.51$2.60
P/E at the last close——
Insider trades, last 12 monthsbought $226,500, sold $62.0 million—
Piotroski F-score—4 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
NewAmsterdam PharmaScynexis
Operating margin
Percent of revenue
NewAmsterdam PharmaScynexis
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
NewAmsterdam PharmaScynexis

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the NewAmsterdam Pharma and Scynexis pages.